11/5/2010

HepaLife Technologies has set up a unit, Alliqua BioMedical, that will focus on developing and commercializing transdermal drug-delivery systems and wound-care products using HepaLife's intellectual property. AquaMed Technologies CEO Matt Harriton has been appointed by HepaLife to serve as the spinoff's chief executive.

Related Summaries